Engineered Anti-prostate Cancer CAR-neutrophils from Human Pluripotent Stem Cells

Overview

Journal J Immunol Regen Med

Specialty Allergy & Immunology

Date 2023 Apr 24

PMID 37089616

Authors

Jackson D Harris

Yun Chang

Ramizah Syahirah

Xiaojun Lance Lian

Qing Deng

Xiaoping Bao

Affiliations

Soon will be listed here.

Abstract

Immunotherapy is a powerful technique where immune cells are modified to improve cytotoxicity against cancerous cells to treat cancers that do not respond to surgery, chemotherapy, or radiotherapy. Expressing chimeric antigen receptor (CAR) in immune cells, typically T lymphocytes, is a practical modification that drives an immune response against cancerous tissue. CAR-T efficacy is suboptimal in solid tumors due to the tumor microenvironment (TME) that limits T lymphocyte cytotoxicity. In this study, we demonstrate that neutrophils differentiated from human pluripotent stem cells modified with AAVS1-inserted CAR constructs showed a robust cytotoxic effect against prostate-specific membrane antigen (PSMA) expressing LNCaP cells as a model for prostate cancer . Our results suggest that engineered CAR can significantly enhance the neutrophil anti-tumor effect, providing a new avenue in treating prostate cancers.

Citing Articles

Adoptive Cell Therapy from the Dish: Potentiating Induced Pluripotent Stem Cells.

Lindenbergh P, van der Stegen S Transfus Med Hemother. 2025; 52(1):27-41.

PMID: 39944411 PMC: 11813279. DOI: 10.1159/000540473.

Forward programming of hPSCs to neutrophils using chemically defined media.

Hall H, Bao X, Dong C, Lian X Stem Cell Res Ther. 2025; 16(1):32.

PMID: 39894817 PMC: 11789356. DOI: 10.1186/s13287-025-04147-2.

Activated neutrophils: A next generation cellular immunotherapy.

Kumbhojkar N, Mitragotri S Bioeng Transl Med. 2025; 10(1):e10704.

PMID: 39801751 PMC: 11711228. DOI: 10.1002/btm2.10704.

Combining the induced pluripotent stem cell (iPSC) technology with chimeric antigen receptor (CAR)-based immunotherapy: recent advances, challenges, and future prospects.

Alidadi M, Barzgar H, Zaman M, Paevskaya O, Metanat Y, Khodabandehloo E Front Cell Dev Biol. 2024; 12:1491282.

PMID: 39624236 PMC: 11609223. DOI: 10.3389/fcell.2024.1491282.

Novel immunotherapeutic approaches in gastric cancer.

Yang M, Lin W, Huang J, Mannucci A, Luo H Precis Clin Med. 2024; 7(4):pbae020.

PMID: 39397869 PMC: 11467695. DOI: 10.1093/pcmedi/pbae020.

References

Yanagimachi M, Niwa A, Tanaka T, Honda-Ozaki F, Nishimoto S, Murata Y . Robust and highly-efficient differentiation of functional monocytic cells from human pluripotent stem cells under serum- and feeder cell-free conditions. PLoS One. 2013; 8(4):e59243. PMC: 3616072. DOI: 10.1371/journal.pone.0059243. View

Yu S, Yi M, Qin S, Wu K . Next generation chimeric antigen receptor T cells: safety strategies to overcome toxicity. Mol Cancer. 2019; 18(1):125. PMC: 6701025. DOI: 10.1186/s12943-019-1057-4. View

Parker S, Diaz I, Anderson K, Batt C . Design, production, and characterization of a single-chain variable fragment (ScFv) derived from the prostate specific membrane antigen (PSMA) monoclonal antibody J591. Protein Expr Purif. 2013; 89(2):136-45. DOI: 10.1016/j.pep.2013.02.016. View

Chang Y, Syahirah R, Oprescu S, Wang X, Jung J, Cooper S . Chemically-defined generation of human hemogenic endothelium and definitive hematopoietic progenitor cells. Biomaterials. 2022; 285:121569. PMC: 10065832. DOI: 10.1016/j.biomaterials.2022.121569. View

Sung H, Ferlay J, Siegel R, Laversanne M, Soerjomataram I, Jemal A . Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA Cancer J Clin. 2021; 71(3):209-249. DOI: 10.3322/caac.21660. View

Chen Y, Yu Z, Tan X, Jiang H, Xu Z, Fang Y . CAR-macrophage: A new immunotherapy candidate against solid tumors. Biomed Pharmacother. 2021; 139:111605. DOI: 10.1016/j.biopha.2021.111605. View

Gill S, Maus M, Porter D . Chimeric antigen receptor T cell therapy: 25years in the making. Blood Rev. 2015; 30(3):157-67. DOI: 10.1016/j.blre.2015.10.003. View

Klichinsky M, Ruella M, Shestova O, Lu X, Best A, Zeeman M . Human chimeric antigen receptor macrophages for cancer immunotherapy. Nat Biotechnol. 2020; 38(8):947-953. PMC: 7883632. DOI: 10.1038/s41587-020-0462-y. View

Chang S, Reuter V, Heston W, Bander N, Grauer L, Gaudin P . Five different anti-prostate-specific membrane antigen (PSMA) antibodies confirm PSMA expression in tumor-associated neovasculature. Cancer Res. 1999; 59(13):3192-8. View

10.

Falloon J, Gallin J . Neutrophil granules in health and disease. J Allergy Clin Immunol. 1986; 77(5):653-62. DOI: 10.1016/0091-6749(86)90404-5. View

11.

Newick K, Moon E, Albelda S . Chimeric antigen receptor T-cell therapy for solid tumors. Mol Ther Oncolytics. 2016; 3:16006. PMC: 4849432. DOI: 10.1038/mto.2016.6. View

12.

Montagner I, Penna A, Fracasso G, Carpanese D, Pieta A, Barbieri V . Anti-PSMA CAR-engineered NK-92 Cells: An Off-the-shelf Cell Therapy for Prostate Cancer. Cells. 2020; 9(6). PMC: 7349573. DOI: 10.3390/cells9061382. View

13.

Henriquez I, Roach 3rd M, Morgan T, Bossi A, Gomez J, Abuchaibe O . Current and Emerging Therapies for Metastatic Castration-Resistant Prostate Cancer (mCRPC). Biomedicines. 2021; 9(9). PMC: 8468423. DOI: 10.3390/biomedicines9091247. View

14.

Barrett D, Singh N, Porter D, Grupp S, June C . Chimeric antigen receptor therapy for cancer. Annu Rev Med. 2013; 65:333-47. PMC: 4120077. DOI: 10.1146/annurev-med-060512-150254. View

15.

Hassani M, Taheri F, Sharifzadeh Z, Arashkia A, Hadjati J, van Weerden W . Construction of a chimeric antigen receptor bearing a nanobody against prostate a specific membrane antigen in prostate cancer. J Cell Biochem. 2019; 120(6):10787-10795. DOI: 10.1002/jcb.28370. View

16.

Kuratsukuri K, Sone T, Wang C, Nishisaka N, Jones R, Haas G . Inhibition of prostate-specific membrane antigen (PSMA)-positive tumor growth by vaccination with either full-length or the C-terminal end of PSMA. Int J Cancer. 2002; 102(3):244-9. DOI: 10.1002/ijc.10700. View

17.

Sadelain M, Brentjens R, Riviere I . The basic principles of chimeric antigen receptor design. Cancer Discov. 2013; 3(4):388-98. PMC: 3667586. DOI: 10.1158/2159-8290.CD-12-0548. View

18.

Li Y, Hermanson D, Moriarity B, Kaufman D . Human iPSC-Derived Natural Killer Cells Engineered with Chimeric Antigen Receptors Enhance Anti-tumor Activity. Cell Stem Cell. 2018; 23(2):181-192.e5. PMC: 6084450. DOI: 10.1016/j.stem.2018.06.002. View

19.

Brok-Volchanskaya V, Bennin D, Suknuntha K, Klemm L, Huttenlocher A, Slukvin I . Effective and Rapid Generation of Functional Neutrophils from Induced Pluripotent Stem Cells Using ETV2-Modified mRNA. Stem Cell Reports. 2019; 13(6):1099-1110. PMC: 6915846. DOI: 10.1016/j.stemcr.2019.10.007. View

20.

June C, Sadelain M . Chimeric Antigen Receptor Therapy. N Engl J Med. 2018; 379(1):64-73. PMC: 7433347. DOI: 10.1056/NEJMra1706169. View